Сравнение

Pemvidutide vs. Semaglutid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

910463-68-2

Молекулярная масса

нет данных

4113.6 g/mol

Период полувыведения

нет данных

165 h

Последовательность

нет данных

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

Механизм действия

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Доказательная база

Наивысшая доказательность

Исследование на людях

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Pemvidutide	Semaglutid
Швейцария	—	Рецептурный
Германия	Не одобрено	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Pemvidutide and Semaglutid?: Pemvidutide is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pemvidutide or Semaglutid?: The highest available evidence level is "Исследование на людях" for Pemvidutide and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pemvidutide and Semaglutid in Germany and the United States?: Германия: Pemvidutide — Не одобрено, Semaglutid — Рецептурный. США: Pemvidutide — Не одобрено, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Pemvidutide

Semaglutid

Швейцария

—

Рецептурный

Германия

Не одобрено

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Pemvidutide and Semaglutid?

Pemvidutide is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pemvidutide or Semaglutid?

The highest available evidence level is "Исследование на людях" for Pemvidutide and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pemvidutide and Semaglutid in Germany and the United States?

Германия: Pemvidutide — Не одобрено, Semaglutid — Рецептурный. США: Pemvidutide — Не одобрено, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.